Crossmark

Women’s experience receiving drug feedback and adherence counseling in MTN-025/HOPE - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring

Crossref DOI link: https://doi.org/10.1007/s10461-022-03663-z

Published Online: 2022-05-10

Published Print: 2022-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Katz, Ariana Wendy Keel https://orcid.org/0000-0001-5742-4953
Balán, Iván C.

Reddy, Krishnaveni

Etima, Juliane

Weber, Kubashni

Tauya, Thelma

Atujuna, Millicent

Scheckter, Rachel

Ngure, Kenneth

Soto-Torres, Lydia

Mgodi, Nyaradzo

Palanee-Phillips, Thesla

Baeten, Jared M.

van der Straten, Ariane
Funding

Funding for this research was provided by:

National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707)
License Information

Text and Data Mining valid from 2022-05-10

Version of Record valid from 2022-05-10
More Information

Article History

Accepted: 18 March 2022

First Online: 10 May 2022

Declarations

:

: The authors have no conflicts of interest to disclose.

: The study was approved by the Institutional Review Boards at RTI International, all study sites, and was overseen by the regulatory infrastructure of the US National Institutes of Health and the Microbicide Trials Network.

: All study participants provided written informed consent to participate in the study through a consent process approved by local ethical review committees in all research settings.

: All participants were informed that any publication of this study will not use their name or identify them personally.

Document is current

Any future updates will be listed below